- M A van Bokhoven, general practitioner and assistant professor in general practice1,
- C Th B M van Deursen, consultant internal medicine2,
- D W Swinkels, professor of clinical chemistry3
- 1Maastricht University, School for Public Health and Primary Care (CAPHRI), Department of General Practice, 6200 MD Maastricht, Netherlands
- 2Department of Internal Medicine and Gastroenterology, Atrium Medisch Centrum Parkstad, 6401 CX Heerlen, Netherlands
- 3Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, Netherlands
- Correspondence to: M A van Bokhoven loes.vanbokhoven{at}hag.unimaas.nl
- Accepted 6 December 2010
Summary points
Hereditary haemochromatosis is an autosomal recessive disorder with a genetic prevalence of 0.4% in northern Europeans but a much lower clinical penetrance
Those affected are at increased risk of cirrhosis of the liver and hepatocellular carcinoma
Symptoms are often non-specific at presentation and include fatigue and arthropathy
If transferrin saturation and serum ferritin are raised, test for C282Y mutation of the HFE gene
First degree relatives of patients with clinically overt haemochromatosis can be screened for C282Y and H63D polymorphisms
Regular phlebotomy is the main treatment, although newly developed therapeutic approaches show promise
Hereditary haemochromatosis is an autosomal recessive genetic disease in which increased intestinal absorption of iron causes accumulation in tissues, primarily the liver, sometimes leading to organ damage. Liver deposits may result in cirrhosis and even death. A systematic review has shown that about 0.4% of people of northern European descent have the genetic mutation that increases the risk of developing haemochromatosis,1 but the clinical penetrance of the mutation is much lower than the genetic prevalence. Symptoms and signs are initially non-specific, so the disease is often diagnosed at a late stage when substantial organ damage has already occurred. The challenge is to avoid both overdiagnosis and underdiagnosis. Since the discovery of the genetic mutation, new knowledge has come to light on the pathophysiology and course of the disease. This has led to new recommendations on diagnosis and treatment. In addition, new treatments are under evaluation. We review evidence from experimental and observational studies, systematic reviews, and guidelines to summarise for the general reader the clinical presentation, diagnosis, including early screening options, and management of hereditary haemochromatosis.
Sources and selection criteria
Initially, we made an extensive search of Medline, Embase, and the Cochrane Library for papers published until December 2009 using both MESH headings and free text related to hereditary haemochromatosis. …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record







CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Ventilator associated pneumonia
Published 30 May 2012
Re: Restless legs syndrome
Published 30 May 2012
Author's reply
Published 30 May 2012
Re: Full access to trial data holds many benefits and a few pitfalls, conference hears
Published 30 May 2012
Restless Legs Syndrome: Fact or Fiction
Published 30 May 2012
Most responses
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 (12 responses)
Published 10 May 2012 - 23:32
The psychiatric oligarchs who medicalise normality (9 responses)
Published 2 May 2012 - 15:42
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21
The hardest thing: admitting error (7 responses)
Published 2 May 2012 - 12:27